Bacterial 16S rRNA gene sequences from fecal samples of prostate cancer patients treated with enzalutamide and pembrolizumab

We performed 16S rRNA gene sequencing of fecal sample DNA from 23 patients with metastatic castrate resistant prostate cancer (mCRPC) progressing on enzalutamide and initiating treatment with anti-PD-1 (pembrolizumab) to determine whether certain features of the microbiome are associated with treatment response (defined as serum PSA decrease >50% at any time on treatment or radiographic response per RECIST V.1.1). Libraries were prepared using the Ion 16S Metagenomics kit, which has primers targeting the following hypervariable regions: v2, v3, v4, v6-7, v8, and v9. Therefore, each fastq file contains sequences from each of the aforementioned hypervariable regions.